Carcinogenesis Advance Access published online on May 5, 2006
Carcinogenesis, doi:10.1093/carcin/bgl060
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD 21205, USA
* To whom correspondence should be addressed. Human liver cancer, primarily hepatocellular carcinoma (HCC), is both common and lethal. Notable variation in HCC incidence rates worldwide corresponds to the prevalence and pattern of the primary etiologic factors. In summary of decades of collaborative research centered in The Gambia, West Africa, this review explores the independent and combined effects of hepatitis B virus (HBV), hepatitis C virus (HCV) and dietary aflatoxin exposure in the etiology of HCC. Through population surveys, field trials and a series of HCC case-control studies, the patterns and natural history of HBV, HCV and aflatoxin exposures have been defined within this population. These investigations have paralleled and informed the development of molecular biomarkers of these etiologic agents and contributed to understanding the complex mechanisms involved in hepatocarcinogenesis. We discuss preventive approaches to reduce the global burden of HCC, emphasizing the Gambia Hepatitis Intervention Study, a country-wide randomized controlled trial designed to document the efficacy of HB vaccination in preventing HBV infections and HBV-related HCC. By recognizing the synergy of applying molecular techniques to population-based epidemiological studies, the portfolio of Gambian research projects presented provides a model for partnering etiologic and mechanistic investigations with applied research.
Received January 20, 2006
Revised April 21, 2006
Accepted April 24, 2006
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa
Gregory D. Kirk 1 *,
Ebrima Bah 2,
and
Ruggero Montesano 3
2 Gambia Hepatitis Intervention Study, MRC Laboratories, PO Box 273, Fajara, The Gambia
3 Via dei Giardini 24, 11013 Courmayeur, Italy
Gregory D. Kirk, E-mail: gkirk{at}jhsph.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Viviani, P. Carrieri, E. Bah, A. J. Hall, G. D. Kirk, M. Mendy, R. Montesano, A. Plymoth, O. Sam, M. Van der Sande, et al. 20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3216 - 3223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Loeb and C. C. Harris Advances in Chemical Carcinogenesis: A Historical Review and Prospective Cancer Res., September 1, 2008; 68(17): 6863 - 6872. [Full Text] [PDF]
|
|
|
|
 |
|
 C. S Rabkin Molecular Epidemiology of Infection-Related Malignancy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 359 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Chen, S. Y. Kuang, P. A. Egner, J. H. Lu, Y. R. Zhu, J. B. Wang, B. C. Zhang, T. Y. Chen, A. Munoz, T. W. Kensler, et al. Acceleration to Death from Liver Cancer in People with Hepatitis B Viral Mutations Detected in Plasma by Mass Spectrometry Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1213 - 1218. [Abstract] [Full Text] [PDF]
|
|